Study of iparomlimab and tuvonralimab plus chemo for hard-to-remove lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy can shrink stage III lung cancer that cannot be surgically removed, making it possible to operate. It is for people who have not had prior treatment for their lung cancer and are healthy enough for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have stage III non-small cell lung cancer that doctors have said cannot be fully removed with surgery.
- You have not had any prior chemotherapy, immunotherapy, or radiation for this lung cancer.
- You are in good enough health to walk and do daily activities (ECOG score 0 or 1).
- Your lung function tests show FEV1 more than 1.0 liter and above 40% of normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
Hear when a new NSCLC (Non-small-cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.